This indication for MCC received Fast Monitor designation by the FDA this past year.. Bioniche Life Sciences revise on Stage III clinical system for evaluating Urocidin Bioniche Existence Sciences Inc. , a research-centered, technology-driven Canadian biopharmaceutical business, today provided an upgrade on its Stage III clinical program analyzing Urocidin in the treating bladder malignancy. THE INFO Monitoring Committee kept its ninth meeting concerning this clinical trial the other day.The latter is named the autoimmune hypothesis. This is the hypothesis that the researchers coming from the Institutes of General Pathology, Anatomy and Microbiology of the Catholic University of Rome have already been tests with their two-year long work. To show the viability of the idea, researchers have fooled the mouse disease fighting capability, modifying subtly a bacterium of the normal family of mycobacteria to create it appear to be to myelin, the proteins coating nerve cells. This modified mycobacterium is totally innocuous. As all external agents, though, it is competent to trigger the result of the T-cells of the immune systems. They intervene to destroy it.